FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007652017> ?p ?o ?g. }

• W2007652017 abstract "Background: A phase III randomised EORTC trial combining systemic chemotherapy and regional hyperthermia (RHT) for patients (n=341) with locally-advanced high-risk soft tissue sarcoma (STS) showed that – compared to chemotherapy alone – the addition of RHT yields a statistically significant improvement in tumor response, with doubling of disease free and local progression free survival (ASCO 2007). A phase II study in chemo-pretreated patients with STS receiving 2nd line ICE chemotherapy (ifosfamide + carboplatin + etoposide) showed clinical activity with no further toxicity if combined with RHT (ASCO 2009). The biological rationale of this approach is based on the direct cytotoxicity of heat and its chemosensitizing effect on tumor cells. Cells respond to heat by producing increasing amounts of molecular chaperones (heat shock proteins, HSPs). Some HSPs, in particular HSP70, are heat-inducible and are released by necrosis, where outside the cells they gain potent immunostimulatory functions. We provided strong evidence that heat up-regulated expression of HSP70 correlates with enhanced susceptibility to NK cell lysis of tumor cells. Besides recognizing of HSP70 on tumors as a target structure, it has been shown that NK cells can be activated ex vivo by the HSP70-derived 14-mer peptide (TKD), enhancing NK immune function. A phase I clinical study showed that reinfusion of autologous NK cells activated ex vivo by TKD in patients with advanced disease is well tolerated, feasible and initiates cytolytic activity of NK cells. In summary, this is a strong rationale that hyperthermia might have a positive impact on the immune system within the context of the heat shock response. We are implementing a prospective randomised study that investigates the impact of autologous TKD-activated NK cells adoptively transferred in patients with high-risk STS responding to chemotherapy and RHT. In a preliminary study we investigated the number and lytic activity of NK cells in patients with high-risk STS. Patients and methods: Patients at primary diagnosis were scheduled to receive an anthracyclin and ifosfamide-based first-line chemotherapy and RHT; patients with progressive disease were scheduled to receive a 2nd line regimen (ICE) and RHT. Informed consent was obtained from all patients. Blood samples taken before the start of therapy were investigated for changes in lymphocyte subpopulations and for their lytic activity cells before and after therapy. Results: Between April 2007 and December 2008 7 1st-line and 14 2nd-line patients were enrolled. 1. A progressive reduction in absolute NK cell counts but no relevant changes in total lymphocyte counts were observed over the applied cycles in second-line patients. 2. Whereas NK mediated lytic activity against K562 is detectable in healthy donors, the spontaneous NK cell activity in all but one second-line patients was completely abrogated at the start of the therapy and was not restored over 4 cycles of ICE+RHT. 3. First-line patients also showed a significant decrease in NK cell activity compared to healthy donors 4. In vitro stimulation of patients9 NK cells with IL-2/TKD induced a highly significant increase in NK cell activity against K562 cells in first- and second-line patients, indicating that NK cells preserve their ability to be activated in vitro. Most interestingly, this ability persisted over the applied cycles of thermochemotherapy. Conclusions: STS patients have suppression of NK cell activity but this lytic activity can be repristinated in vivo after stimulation with TKD/IL-2. Translational studies are performed to further elucidate the potential role of hyperthermia in promoting an antitumor immune response. Citation Information: Clin Cancer Res 2010;16(7 Suppl):B11" @default.
• W2007652017 created "2016-06-24" @default.
• W2007652017 creator A5041376830 @default.
• W2007652017 creator A5072612103 @default.
• W2007652017 creator A5085688218 @default.
• W2007652017 date "2010-04-01" @default.
• W2007652017 modified "2023-09-25" @default.
• W2007652017 title "Abstract B11: Hyperthermia and antitumor immunity" @default.
• W2007652017 doi "https://doi.org/10.1158/1078-0432.tcme10-b11" @default.
• W2007652017 hasPublicationYear "2010" @default.
• W2007652017 type Work @default.
• W2007652017 sameAs 2007652017 @default.
• W2007652017 citedByCount "0" @default.
• W2007652017 crossrefType "proceedings-article" @default.
• W2007652017 hasAuthorship W2007652017A5041376830 @default.
• W2007652017 hasAuthorship W2007652017A5072612103 @default.
• W2007652017 hasAuthorship W2007652017A5085688218 @default.
• W2007652017 hasConcept C104317684 @default.
• W2007652017 hasConcept C109316439 @default.
• W2007652017 hasConcept C126322002 @default.
• W2007652017 hasConcept C150903083 @default.
• W2007652017 hasConcept C151730666 @default.
• W2007652017 hasConcept C202751555 @default.
• W2007652017 hasConcept C203014093 @default.
• W2007652017 hasConcept C205260736 @default.
• W2007652017 hasConcept C207001950 @default.
• W2007652017 hasConcept C26291073 @default.
• W2007652017 hasConcept C2776694085 @default.
• W2007652017 hasConcept C2778119113 @default.
• W2007652017 hasConcept C2779343474 @default.
• W2007652017 hasConcept C2779949491 @default.
• W2007652017 hasConcept C502942594 @default.
• W2007652017 hasConcept C55493867 @default.
• W2007652017 hasConcept C71924100 @default.
• W2007652017 hasConcept C73588182 @default.
• W2007652017 hasConcept C86803240 @default.
• W2007652017 hasConcept C8891405 @default.
• W2007652017 hasConceptScore W2007652017C104317684 @default.
• W2007652017 hasConceptScore W2007652017C109316439 @default.
• W2007652017 hasConceptScore W2007652017C126322002 @default.
• W2007652017 hasConceptScore W2007652017C150903083 @default.
• W2007652017 hasConceptScore W2007652017C151730666 @default.
• W2007652017 hasConceptScore W2007652017C202751555 @default.
• W2007652017 hasConceptScore W2007652017C203014093 @default.
• W2007652017 hasConceptScore W2007652017C205260736 @default.
• W2007652017 hasConceptScore W2007652017C207001950 @default.
• W2007652017 hasConceptScore W2007652017C26291073 @default.
• W2007652017 hasConceptScore W2007652017C2776694085 @default.
• W2007652017 hasConceptScore W2007652017C2778119113 @default.
• W2007652017 hasConceptScore W2007652017C2779343474 @default.
• W2007652017 hasConceptScore W2007652017C2779949491 @default.
• W2007652017 hasConceptScore W2007652017C502942594 @default.
• W2007652017 hasConceptScore W2007652017C55493867 @default.
• W2007652017 hasConceptScore W2007652017C71924100 @default.
• W2007652017 hasConceptScore W2007652017C73588182 @default.
• W2007652017 hasConceptScore W2007652017C86803240 @default.
• W2007652017 hasConceptScore W2007652017C8891405 @default.
• W2007652017 hasLocation W20076520171 @default.
• W2007652017 hasOpenAccess W2007652017 @default.
• W2007652017 hasPrimaryLocation W20076520171 @default.
• W2007652017 hasRelatedWork W1988318735 @default.
• W2007652017 hasRelatedWork W2009890004 @default.
• W2007652017 hasRelatedWork W2042628330 @default.
• W2007652017 hasRelatedWork W2091972228 @default.
• W2007652017 hasRelatedWork W2162284427 @default.
• W2007652017 hasRelatedWork W2180202213 @default.
• W2007652017 hasRelatedWork W2258216786 @default.
• W2007652017 hasRelatedWork W2395243067 @default.
• W2007652017 hasRelatedWork W2425260309 @default.
• W2007652017 hasRelatedWork W2473549004 @default.
• W2007652017 hasRelatedWork W2521900852 @default.
• W2007652017 hasRelatedWork W2551594467 @default.
• W2007652017 hasRelatedWork W2572907271 @default.
• W2007652017 hasRelatedWork W2621884310 @default.
• W2007652017 hasRelatedWork W2751623946 @default.
• W2007652017 hasRelatedWork W2797789131 @default.
• W2007652017 hasRelatedWork W2911550206 @default.
• W2007652017 hasRelatedWork W2913551994 @default.
• W2007652017 hasRelatedWork W2986854277 @default.
• W2007652017 hasRelatedWork W3026299954 @default.
• W2007652017 isParatext "false" @default.
• W2007652017 isRetracted "false" @default.
• W2007652017 magId "2007652017" @default.
• W2007652017 workType "article" @default.